Today, the Executive V P& CFO of Omnicell (OMCL), Kuipers Peter, sold shares of OMCL for $1.87M.
Following Kuipers Peter J.’s last OMCL Sell transaction on December 10, 2018, the stock climbed by 13.4%. In addition to Kuipers Peter, 6 other OMCL executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Omnicell’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $212 million and quarterly net profit of $14.79 million. In comparison, last year the company earned revenue of $198 million and had a net profit of $24.29 million. OMCL’s market cap is $3.39B and the company has a P/E ratio of 91.22. Currently, Omnicell has an average volume of 290.2K.
One of the top 25 analysts, according to TipRanks.com, recently recommended Buy OMCL with a $91 price target. Based on 3 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $82.33, reflecting a -1.9% downside.
The insider sentiment on Omnicell has been negative according to 78 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omnicell, Inc. engages in the provision of medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions. It operates through Automation & Analytics and Medication Adherence segments.